Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis
ME Rothenberg, T Wen, A Greenberg, O Alpan… - Journal of Allergy and …, 2015 - Elsevier
Background Eosinophilic esophagitis (EoE) is a chronic allergic disease with limited
treatment options. Objective We evaluated QAX576, an mAb against IL-13, in the treatment
of patients with EoE. Methods Patients (18-50 years) with proton pump inhibitor–resistant
esophageal eosinophilia received intravenous QAX576 (6 mg/kg) or placebo (2: 1) at weeks
0, 4, and 8 and were followed for 6 months. The primary end point was the responder rate for
a greater than 75% decrease in peak eosinophil counts at week 12. Efficacy was to be …
treatment options. Objective We evaluated QAX576, an mAb against IL-13, in the treatment
of patients with EoE. Methods Patients (18-50 years) with proton pump inhibitor–resistant
esophageal eosinophilia received intravenous QAX576 (6 mg/kg) or placebo (2: 1) at weeks
0, 4, and 8 and were followed for 6 months. The primary end point was the responder rate for
a greater than 75% decrease in peak eosinophil counts at week 12. Efficacy was to be …